Hologicの空売り状況は、投資家がHologicの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Hologic (NASDAQ:HOLX) 株価情報, 空売り情報

Hologic

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Hologic Inc

News

HOLX

Hologic Granted FDA Clearance For Aptima SARS-CoV-2 Assay

<p>Raymond James  analyst Andrew Cooper   reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and lowers the price target from $95 to $90.</p>


Price Target

Reiteration

Analyst Ratings

Raymond James Reiterates Outperform on Hologic, Lowers Price Target to $90

<p>RBC Capital  analyst Conor McNamara   maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Sector Perform and lowers the price target from $88 to $85.</p>


RBC Capital Maintains Sector Perform on Hologic, Lowers Price Target to $85

<p>Evercore ISI Group  analyst Vijay Kumar   maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a In-Line and lowers the price target from $76 to $73.</p>


Evercore ISI Group Maintains In-Line on Hologic, Lowers Price Target to $73

<p>Stephens &amp; Co.  analyst Mason Carrico   reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Overweight and maintains $84 price target.</p>


Stephens & Co. Reiterates Overweight on Hologic, Maintains $84 Price Target

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Evercore ISI Group raised <strong>Arm Holdings plc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) price target from $176 to $202. Evercore ISI Group analyst Mark Lipacis maintained an Outperform rating. Arm shares closed at $173.26 on Wednesday. <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for <strong>Amgen Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) from $256 to $275. B of A Securities analyst Tim Anderson maintained an Underperform rating. Amgen shares closed at $307.81 on Wednesday. <a href="https://www.benzinga.com/quote/AMGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital boosted <strong>Fiserv, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) price target from $233 to $260. BMO Capital analyst Rufus Hone maintained an Outperform rating. Fiserv shares closed at $229.53 on Wednesday. <a href="https://www.benzinga.com/quote/FI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised the price target for <strong>Coherent Corp</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) from $105 to $115. Rosenblatt analyst Mike Genovese maintained a Neutral rating. Coherent shares closed at $90.10 on Wednesday. <a href="https://www.benzinga.com/quote/COHR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Northland Capital Markets cut the price target for <strong>CSG Systems International, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGS#NASDAQ">CSGS</a>) from $78 to $80. Northland Capital Markets analyst Nehal Chokshi reiterated an Outperform rating. CSG Systems shares closed at $61.66 on Wednesday. S<a href="https://www.benzinga.com/quote/CSGS/analyst-ratings">ee how other analysts view this stoc</a>k.</li>
<li>Piper Sandler slashed <strong>Skyworks Solutions, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) price target from $85 to $70. Piper Sandler analyst Harsh Kumar maintained a Neutral rating. Skyworks shares settled at $87.08 on Wednesday. <a href="https://www.benzinga.com/quote/SWKS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut <strong>PepsiCo, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) price target from $158 to $153. Barclays analyst Lauren Lieberman maintained an Overweight rating. PepsiCo shares closed at $145.66 on Wednesday. <a href="https://www.benzinga.com/quote/PEP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners cut <strong>Hologic, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) price target from $80 to $75. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. Hologic shares closed at $72.80 on Wednesday.  <a href="https://www.benzinga.com/quote/HOLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised the price target for <strong>Workday, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) from $300 to $310. Goldman Sachs analyst Kash Rangan maintained a Buy rating. Workday shares settled at $276.17 on Wednesday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler slashed <strong>Uber Technologies, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) price target from $82 to $80. Piper Sandler analyst Thomas Champion maintained an Overweight rating. Uber shares closed at $64.48 on Wednesday. <a href="https://www.benzinga.com/quote/UBER/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></strong></li>
</ul>


Pre-Market Outlook

Markets

Trading Ideas

AMGN

COHR

CSGS

SWKS

UBER

WDAY

Uber To $80? Here Are 10 Top Analyst Forecasts For Thursday

<p>U.S. stock futures were higher this morning, with the Dow Jones futures gaining around 100 points on Thursday.</p>
<p>Shares of <strong>Ford Motor Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) fell sharply in today's pre-market trading after the company said that it expects $5 billion to $5.5 billion in losses in its EV segment this year, in line with the loss <a href="https://www.benzinga.com/tech/25/02/43522408/ford-slides-5-pre-market-after-disappointing-outlook-high-loss-from-ev-segment-in-2024">recorded last year</a>.</p>
<p>Ford said it sees full-year 2025 adjusted EBIT in a range of $7 billion to $8.5 billion, adjusted free cash flow in a range of $3.5 billion to $4.5 billion, and capital spending in a range of $8 billion to $9 billion.</p>
<p>Meanwhile, Ford reported upbeat fourth-quarter financial results on Wednesday.</p>
<p>Ford Motor shares dipped 6.1% to $9.40 in the pre-market trading session.</p>
<p>Here are some other stocks moving lower in pre-market trading.</p>
<ul>
<li><strong>Skyworks Solutions, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) dipped 29.2% to $61.65 in pre-market trading after the company issued second-quarter adjusted EPS guidance below estimates..</li>
<li><strong>FormFactor, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) fell 27.7% to $29.78 in today's pre-market trading after the company reported worse-than-expected fourth-quarter adjusted EPS results and issued cirst-quarter guidance below estimates.</li>
<li><strong>Matrix Service Company</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTRX#NASDAQ">MTRX</a>) shares fell 26.1% to $10.38 in pre-market trading after the company reported second-quarter financial results and cut its FY25 sales guidance below estimates.</li>
<li><strong>SunCar Technology Group Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDA#NASDAQ">SDA</a>) fell 18.3% to $6.90 in pre-market trading after the company reported the pricing of $50 million follow-on public offering of class a ordinary shares.   </li>
<li><strong>Symbotic Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) fell 16.6% to $25.80 in pre-market trading. Symbotic reported quarterly losses of three cents per share which missed the analyst consensus estimate for losses of two cents. Quarterly revenue of $486.69 million also missed the analyst consensus estimate of $490.98 million.</li>
<li><strong>Mach Natural Resources LP</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) declined 6.9% to $16.00 in pre-market trading as the company announced the launch of 12 million common unit offering.</li>
<li><strong>Mineralys Therapeutics, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) fell 5.5% to $9.70 in pre-market trading. Mineralys Therapeutics will report its financial results from the fourth quarter, before the opening bell on Wednesday, Feb. 12.</li>
<li><strong>Hologic, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) slipped 4.9% to $69.22 in pre-market trading following quarterly results.</li>
<li><strong>QUALCOMM Incorporated</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) fell 4.7% to $167.50 in pre-market trading following first-quarter results.</li>
<li><strong>Arm Holdings plc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) fell 4.2% to $166.06 in pre-market trading. Arm Holdings reported better-than-expected third-quarter financial results for fiscal year 2025 after the market closed on Wednesday. Arm said it expects fourth-quarter revenue of $1.175 billion to $1.275 billion. The company anticipates fourth-quarter adjusted earnings of 48 cents to 56 cents per share. The company also narrowed its full-year guidance.</li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></strong></li>
</ul>


Movers

FORM

MLYS

MTRX

QCOM

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

Ford, Skyworks Solutions, FormFactor And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

<p>Leerink Partners  analyst Puneet Souda   downgrades Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Outperform to Market Perform and lowers the price target from $80 to $75.</p>


Downgrades

Leerink Partners Downgrades Hologic to Market Perform, Lowers Price Target to $75

WIIM

Hologic shares are trading lower after the company cut its FY25 revenue outlook.

<p>Needham  analyst Mike Matson   reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Hold to Hold.</p>


Needham Reiterates Hold on Hologicto Hold

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) reported its Q1 earnings results on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

Hologic Q1 Earnings Assessment

<p>The Q1 earnings report for <strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) was released on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>The company missed on EPS by $0.0 in the last quarter, resulting in a 6.0% drop share price change the following day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Hologic Q1

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) just disclosed its Q1 earnings on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hologic Q1 Earnings Summary & Key Takeaways

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) announced its Q1 earnings on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hologic Earnings Report: Q1 Overview

Guidance

Hologic Expects Q2 Revenue Of $995M - $1.005B (Est $1.036B), Adj EPS Of $1.00 - $1.03 ((Est $1.03)

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) just disclosed its Q1 earnings on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed on EPS by $0.0 which was followed by a 6.0% drop in the share price the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hologic Earnings Review: Q1 Summary

Hologic Cuts FY25 Revenue Outlook From $4.15B - $4.20B To $4.05B - $4.10B, Est $4.162B

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) reported its Q1 earnings results on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>Last quarter the company missed on EPS by $0.0 which was followed by a 6.0% drop in the share price the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hologic: Q1 Earnings Insights

<p>The Q1 earnings report for <strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) was released on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: Hologic Q1

<p>"We are reducing our full-year revenue guidance based mainly on currency headwinds and weakness in breast health capital sales, which are outweighing strength in our U.S. diagnostics business," said Karleen Oberton, Hologic's Chief Financial Officer. "At the same time, we are maintaining our full-year guidance for non-GAAP EPS based on strong profitability and execution of our capital allocation strategy."</p>


Comments

Hologic

空売り

Hologic (NASDAQ:HOLX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル